Abstract
Introduction: Spinocerebellar ataxia type 36 (SCA36) is caused by large GGCCTG repeat expansion in the NOP56 gene. The genetic diagnosis based on Southern blot is expensive and time-consuming. This study aimed to evaluate the reliability and effectiveness of whole exome sequencing (WES) for routine genetic diagnosis of suspected SCA36 patients. Methods: Pathogenic repeat expansions for SCAs including SCA36 were first analyzed based on WES data using ExpansionHunter in five probands from SCA families, then the results were confirmed by triplet repeat primed polymerase chain reaction (TP-PCR) and Southern blot. Results: GGCCTG repeat expansion in NOP56 was indicated in all five probands by WES, then it was found in 11 SCA patients and three asymptomatic individuals by TP-PCR. The sizes of GGCCTG repeat expansions were confirmed to be 1,390–1,556 by Southern blot. The mean age at onset of the patients was 51.0 ± 9.3 (ranging from 41 to 71), and they presented slowly progressive cerebellar ataxia, atrophy and fasciculation in tongue or limb muscles. Conclusion: The patients were clinically and genetically diagnosed as SCA36. This study proposed that WES could be a rapid, reliable, and cost-effective routine test for the preliminarily detection of SCA36 and other ataxia diseases.
Journal Section:
Research Article
References
1.
Coarelli
G
, Wirth
T
, Tranchant
C
, Koenig
M
, Durr
A
, Anheim
M
. The inherited cerebellar ataxias: an update
. J Neurol
. 2023
;270
(1
):208
–22
. 2.
Corral-Juan
M
, Casquero
P
, Giraldo-Restrepo
N
, Laurie
S
, Martinez-Piñeiro
A
, Mateo-Montero
RC
, et al. New spinocerebellar ataxia subtype caused by SAMD9L mutation triggering mitochondrial dysregulation (SCA49)
. Brain Commun
. 2022
;4
(2
):fcac030
. 3.
Tan
D
, Wei
C
, Chen
Z
, Huang
Y
, Deng
J
, Li
J
, et al. CAG repeat expansion in THAP11 is associated with a novel spinocerebellar ataxia
. Mov Disord
. 2023
;38
(7
):1282
–93
. 4.
Lopez
S
, He
F
. Spinocerebellar ataxia 36: from mutations toward therapies
. Front Genet
. 2022
;13
:837690
. 5.
Lee
YC
, Tsai
PC
, Guo
YC
, Hsiao
CT
, Liu
GT
, Liao
YC
, et al. Spinocerebellar ataxia type 36 in the Han Chinese
. Neurol Genet
. 2016
;2
(3
):e68
. 6.
García-Murias
M
, Quintáns
B
, Arias
M
, Seixas
AI
, Cacheiro
P
, Tarrío
R
, et al. “Costa da Morte” ataxia is spinocerebellar ataxia 36: clinical and genetic characterization
. Brain
. 2012
;135
(Pt 5
):1423
–35
. 7.
Ikeda
Y
, Ohta
Y
, Kobayashi
H
, Okamoto
M
, Takamatsu
K
, Ota
T
, et al. Clinical features of SCA36: a novel spinocerebellar ataxia with motor neuron involvement (Asidan)
. Neurology
. 2012
;79
(4
):333
–41
. 8.
Kobayashi
H
, Abe
K
, Matsuura
T
, Ikeda
Y
, Hitomi
T
, Akechi
Y
, et al. Expansion of intronic GGCCTG hexanucleotide repeat in NOP56 causes SCA36, a type of spinocerebellar ataxia accompanied by motor neuron involvement
. Am J Hum Genet
. 2011
;89
(1
):121
–30
. 9.
Aguiar
P
, Pardo
J
, Arias
M
, Quintáns
B
, Fernández-Prieto
M
, Martínez-Regueiro
R
, et al. PET and MRI detection of early and progressive neurodegeneration in spinocerebellar ataxia type 36
. Mov Disord
. 2017
;32
(2
):264
–73
. 10.
Zhang
Y
, Roland
C
, Sagui
C
. Structural and dynamical characterization of DNA and RNA quadruplexes obtained from the GGGGCC and GGGCCT hexanucleotide repeats associated with C9FTD/ALS and SCA36 diseases
. ACS Chem Neurosci
. 2018
;9
(5
):1104
–17
. 11.
Zeng
S
, Zeng
J
, He
M
, Zeng
X
, Zhou
Y
, Liu
Z
, et al. Genetic and clinical analysis of spinocerebellar ataxia type 36 in Mainland China
. Clin Genet
. 2016
;90
(2
):141
–8
. 12.
Rafehi
H
, Szmulewicz
DJ
, Pope
K
, Wallis
M
, Christodoulou
J
, White
SM
, et al. Rapid diagnosis of spinocerebellar ataxia 36 in a three-generation family using short-read whole-genome sequencing data
. Mov Disord
. 2020
;35
(9
):1675
–9
. 13.
Casse
F
, Courtin
T
, Tesson
C
, Ferrien
M
, Noël
S
, Fauret-Amsellem
AL
, et al. Detection of ATXN2 expansions in an exome dataset: an underdiagnosed cause of parkinsonism
. Mov Disord Clin Pract
. 2023
;10
(4
):664
–9
. 14.
Harding
AE
. ClassiClassification of the hereditary ataxias and paraplegiascation of the hereditary ataxias and paraplegias
. Lancet
. 1983
;1
(8334
):1151
–5
. 15.
Maas
RP
, van Gaalen
J
, Klockgether
T
, van de Warrenburg
BP
. The preclinical stage of spinocerebellar ataxias
. Neurology
. 2015
;85
(1
):96
–103
. 16.
Perez-Lloret
S
, van de Warrenburg
B
, Rossi
M
, Rodríguez-Blázquez
C
, Zesiewicz
T
, Saute
JAM
, et al. Assessment of ataxia rating scales and cerebellar functional tests: critique and recommendations
. Mov Disord
. 2021
;36
(2
):283
–97
. 17.
Tian
Y
, Wang
JL
, Huang
W
, Zeng
S
, Jiao
B
, Liu
Z
, et al. Expansion of human-specific GGC repeat in neuronal intranuclear inclusion disease-related disorders
. Am J Hum Genet
. 2019
;105
(1
):166
–76
. 18.
Dong
R
, Wei
X
, Zhang
K
, Song
F
, Lv
Y
, Gao
M
, et al. Genotypic and phenotypic characteristics of 12 Chinese children with glycogen storage diseases
. Front Genet
. 2022
;13
:932760
. 19.
Deng
J
, Yu
J
, Li
P
, Luan
X
, Cao
L
, Zhao
J
, et al. Expansion of GGC Repeat in GIPC1 is associated with oculopharyngodistal myopathy
. Am J Hum Genet
. 2020
;106
(6
):793
–804
. 20.
Ohta
Y
, Ikegami
K
, Sato
K
, Hishikawa
N
, Omote
Y
, Takemoto
M
, et al. Clinical anticipation of disease onset in a Japanese Asidan (SCA36) family
. J Neurol Sci
. 2020
;416
:117043
. 21.
Paulson
H
. Repeat expansion diseases
. Handb Clin Neurol
. 2018
;147
:105
–23
. 22.
Terasaki
A
, Nakamura
M
, Urata
Y
, Hiwatashi
H
, Yokoyama
I
, Yasuda
T
, et al. DNA analysis of benign adult familial myoclonic epilepsy reveals associations between the pathogenic TTTCA repeat insertion in SAMD12 and the nonpathogenic TTTTA repeat expansion in TNRC6A
. J Hum Genet
. 2021
;66
(4
):419
–29
. 23.
Katsimpouris
D
, Kartanou
C
, Breza
M
, Panas
M
, Koutsis
G
, Karadima
G
. Screening for spinocerebellar ataxia type 36 (SCA36) in the Greek population
. J Neurol Sci
. 2019
;402
:131
–2
. 24.
Morimoto
N
, Yamashita
T
, Sato
K
, Kurata
T
, Ikeda
Y
, Kusuhara
T
, et al. Assessment of swallowing in motor neuron disease and Asidan/SCA36 patients with new methods
. J Neurol Sci
. 2013
;324
(1–2
):149
–55
. 25.
Ikeda
Y
, Ohta
Y
, Kurata
T
, Shiro
Y
, Takao
Y
, Abe
K
. Acoustic impairment is a distinguishable clinical feature of Asidan/SCA36
. J Neurol Sci
. 2013
;324
(1–2
):109
–12
. 26.
Xie
Y
, Chen
Z
, Long
Z
, Chen
RT
, Jiang
YZ
, Liu
MJ
, et al. Identification of the largest SCA36 pedigree in Asia: with multimodel neuroimaging evaluation for the first time
. Cerebellum
. 2022
;21
(3
):358
–67
. 27.
Abe
K
, Ikeda
Y
, Kurata
T
, Ohta
Y
, Manabe
Y
, Okamoto
M
, et al. Cognitive and affective impairments of a novel SCA/MND crossroad mutation Asidan
. Eur J Neurol
. 2012
;19
(8
):1070
–8
. 28.
Martínez-Regueiro
R
, Arias
M
, Cruz
R
, Quintáns
B
, Labella-Caballero
T
, Pardo
M
, et al. Cerebellar cognitive affective syndrome in Costa da Morte ataxia (SCA36)
. Cerebellum
. 2020
;19
(4
):501
–9
. 29.
Valera
JM
, Diaz
T
, Petty
LE
, Quintáns
B
, Yáñez
Z
, Boerwinkle
E
, et al. Prevalence of spinocerebellar ataxia 36 in a US population
. Neurol Genet
. 2017
;3
(4
):e174
. 30.
Aydin
G
, Dekomien
G
, Hoffjan
S
, Gerding
WM
, Epplen
JT
, Arning
L
. Frequency of SCA8, SCA10, SCA12, SCA36, FXTAS and C9orf72 repeat expansions in SCA patients negative for the most common SCA subtypes
. BMC Neurol
. 2018
;18
(1
):3
. 31.
Bahlo
M
, Bennett
MF
, Degorski
P
, Tankard
RM
, Delatycki
MB
, Lockhart
PJ
. Recent advances in the detection of repeat expansions with short-read next-generation sequencing
. F1000Res
. 2018
;7
:F1000 Faculty Rev-736
. © 2024 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2024
You do not currently have access to this content.
